TOP TEN perturbations for 1282_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1282_s_at
Selected probe(set): 203942_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1282_s_at (203942_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

prostate cancer study 8 (ptasc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):1.7586517
Number of Samples:2 / 5
Experimental prostate cancer study 8 (ptasc)
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

Treg activation study 1 (300min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):-1.7572851
Number of Samples:2 / 2
Experimental Treg activation study 1 (300min)
Regulatory T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

kidney transplantation study 15 (4 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-1.6862087
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (4 week)
CD14+ monocyte samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

glioma study 16 (LN-215) / normal astrocyte sample

Relative Expression (log2-ratio):1.6585026
Number of Samples:2 / 3
Experimental glioma study 16 (LN-215)
Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):-1.6253529
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

scleroderma study 8 (skin; anifrolumab; 5mg/kg;/wk; multiple dose; 28d) / scleroderma study 8 (skin; anifrolumab; 1mg/kg/wk; multiple dose; 28d)

Relative Expression (log2-ratio):-1.6204519
Number of Samples:2 / 4
Experimental scleroderma study 8 (skin; anifrolumab; 5mg/kg;/wk; multiple dose; 28d)
Skin tissue samples collected from adult systemic sclerosis patients at day 28 after a 4-week repeated intravenous injection of anifrolumab (5 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). ATC code:---
Control scleroderma study 8 (skin; anifrolumab; 1mg/kg/wk; multiple dose; 28d)
Skin tissue samples collected from adult systemic sclerosis patients at day 28 after a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1. ATC code:---

kidney transplantation study 13 (pre) / normal T-cell (CD8+) sample

Relative Expression (log2-ratio):-1.6142836
Number of Samples:4 / 5
Experimental kidney transplantation study 13 (pre)
CD8+ T-cell samples derived from kidney transplant patients pre-transplantation. Samples were collected immediately before transplantation and administration of immunosuppressive therapy.
Control normal T-cell (CD8+) sample
CD8+ T-cell samples derived from healthy control subjects.

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):1.599268
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

TCDD study 1 (24h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-1.5969172
Number of Samples:3 / 7
Experimental TCDD study 1 (24h)
HepG2 cells exposed to 10nM 2,3,7,8-tetrachloro dibenzo-p-dioxin (TCDD) in DMSO solvent for 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 24 hours.

wound healing study 2 (in vivo) / control skin tissue (in vivo)

Relative Expression (log2-ratio):1.5618238
Number of Samples:3 / 3
Experimental wound healing study 2 (in vivo)
Skin wound samples obtained by punch biopsy from the edge of the original biopsies after four days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. To possible remove infiltrating inflammatory cells before RNA isolation the samples were washed in NaCl.
Control control skin tissue (in vivo)
Control non-wounded skin samples obtained by punch biopsy from healthy donors. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. To possible remove infiltrating inflammatory cells before RNA isolation the samples were washed in NaCl.